表紙
市場調査レポート

中国のブデソニド市場の分析

Investigation Report on China Budesonide Market, 2010-2019

発行 China Research and Intelligence 商品コード 296859
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
中国のブデソニド市場の分析 Investigation Report on China Budesonide Market, 2010-2019
出版日: 2015年06月11日 ページ情報: 英文 30 Pages
概要

ブデソニド(Budesonide)の吸入停止(商標名「Pulmicort Respules」)はAstra Zenecaが開発し、ぜんそくの治療薬として米国FDA(食品医薬品局)の販売認証を2000年に獲得したものです。中国でも2001年に認証されました。中国国内には現在、呼吸器系疾患の患者が3億人近く存在しており、そのうち5,000万人が咳の症状を訴え、年4%の割合で増加しています。また、1,500〜2,000万人が喘息を患っています。それを受けて中国のブデソニド市場の年平均(CAGR)成長率(2005〜2014年)は29%に達し、依然として莫大な需要を誇っています。

当レポートでは、中国におけるブデソニド市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果をお届けします。

第1章 ブデソニドの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国でのブデソニド市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 ブデソニドの売上高の分析

  • 売上高
    • 総売上高
    • 地域別
  • 販売量
    • 総販売量
    • 地域別

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 ブデソニドの病院向け基準価格(企業別)

  • SYNMOSA BIOPHARMA CORPORATION (TW)
  • WELLCOME AUSTRALIA LTD.(AU)
  • Shanghai Sine Pharmaceutical Co Ltd
  • Orion Corporation
  • Astra AB (Sweden)
  • Lunan Better Pharmaceutical Co., Ltd

第7章 主要メーカーの分析

  • Shanghai Sine Pharmaceutical Co Ltd
  • Lunan Better Pharmaceutical Co., Ltd.
  • Astra AB (Sweden)
  • WELLCOME AUSTRALIA LTD.(AU)
  • AstraZeneca Australia
  • AstraZeneca plc.
  • Lunan Better Pharmaceutical Co., Ltd.
  • SYNMOSA BIOPHARMA CORPORATION

第8章 中国のブデソニド市場の将来展望

  • 市場規模の予測
  • 市場競争の予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1506210

With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma, more so in industrialized countries and regions where tobacco consumption is high. 5% of adults and 20% of children there have been attacked by this disease and many of them come down with bronchial asthma induced by chronic cough.

Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.

Budesonide, an adrenocortical hormone, was developed by Astrazeneca in the 1990s. It is mainly used for the treatment of non-glucocorticoid dependent or glucocorticoid-dependent bronchial asthma and chronic obstructive pulmonary disease (COPD). In Jun. 1997, budesonide aerosol got FDA's approval. In recent years, with the steady growth of global demand, budesonide has occupied an important position in the TOP10 respiratory drugs.

In 1994, China approved the import of budesonide for clinical purposes. After being marketed by Astra (Wuxi) in China in 1995, budesonide develops fast with annual sales rising from CNY 60 million in 2005 to CNY 595 million in 2014 and CAGR reaching up to 29% during the period of 2005-2014. Budesonide enjoys a vast demand in China. Currently, budesonide in the Chinese market mainly come from the following companies: Lunan Better Pharmaceutical Co., Ltd, Orion Corporation (Finland), WELLCOME AUSTRALIA LTD.(AU), SYNMOSA BIOPHARMA CORPORATION (TW) and Astra AB (Sweden). While they all take up certain shares in the market, WELLCOME AUSTRALIA LTD.(AU) has the largest market share of 88% with sales value reaching up to CNY 524 million in 2014.

The market size of budesonide in China is expected to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of budesonide in China
  • market share of manufacturers of budesonide in China
  • price of budesonide in Chinese market
  • major manufacturers of budesonide in Chinese market
  • market outlook of budesonide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of cortin drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Budesonide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Budesonide in China

  • 2.1. Patent and Approval Status of Budesonide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Budesonide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Budesonide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Budesonide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Budesonide in Chinese Hospitals in 2014

  • 6.1. SYNMOSA BIOPHARMA CORPORATION (TW) (Trade Name: Rhinocort)
  • 6.2. WELLCOME AUSTRALIA LTD.(AU)
  • 6.2. WELLCOME AUSTRALIA LTD.(AU)
  • 6.3. Shanghai Sine Pharmaceutical Co Ltd (Trade Name: Bao Yi Su)
  • 6.4. Orion Corporation (Finland) (Trade Name: Antrex)
  • 6.5. Astra AB (Sweden) (Trade Name: Pulmicort)
  • 6.6. Lunan Better Pharmaceutical Co., Ltd (Trade Name: Ji Shu)

7. Major Manufacturers of Budesonide in Chinese Market, 2010-2014

  • 7.1. Shanghai Sine Pharmaceutical Co Ltd
  • 7.2. Lunan Better Pharmaceutical Co., Ltd
  • 7.3. Astra AB (Sweden)
  • 7.4. WELLCOME AUSTRALIA LTD
  • 7.4. WELLCOME AUSTRALIA LTD
  • 7.5. SYNMOSA BIOPHARMA CORPORATION
  • 7.5. SYNMOSA BIOPHARMA CORPORATION

8. Market Outlook of Budesonide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Budesonide in China
  • Chart Approval Information of Budesonide in China
  • Chart Sales Status of Budesonide in China
  • Chart Sales Value of Budesonide in China, 2010-2014
  • Chart Sales Value of Budesonide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Budesonide in China, 2010-2014
  • Chart Market Share of TOP4 Manufacturers of Budesonide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Budesonide Made by WELLCOME AUSTRALIA LTD.(AU) in China, 2010-2014
  • Chart Sales Value and Market Share of Budesonide Made by Astra (Sweden) in China, 2010-2014
  • Chart Sales Value and Market Share of Budesonide Made by Lunan Better in China, 2010-2014
  • Chart Sales Value and Market Share of Budesonide Made by SYNMOSA(TW) in China, 2010-2014
  • Chart Sales Value and Market Share of Budesonide Nasal Spray in China, 2010-2014
  • Chart Sales Value and Market Share of Budesonide Aerosol in China, 2010-2014
  • Chart Price of Budesonide Made by SYNMOSA BIOPHARMA CORPORATION (TW) in Some Chinese Cities in 2014
  • Chart Price of Budesonide Made by WELLCOME AUSTRALIA LTD.(AU) in Some Chinese Cities in 2014
  • Chart Price of Budesonide Made by Sine in Some Chinese Cities in 2014
  • Chart Price of Budesonide Made by Orion Corporation (Finland) in Some Chinese Cities in 2014
  • Chart Price of Budesonide Made by Astra AB (Sweden) in Some Chinese Cities in 2014
  • Chart Price of Budesonide Made by Lunan Better Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top